5.04.2021, 13:03

SPH Sales revenues for March 2021

Sofia, Bulgaria, April 5, 2021 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for March 2021 the Company recorded a decrease in sales of 56% compared to the same month of 2020, incl. 55% decrease in domestic sales and 12% decrease in export sales.

Załączniki

Pobierz załącznik 1

Inne komunikaty

Data	Tytuł	Kurs	Zmiana
2024-04-25	SPH Publication of Annual consolidated audited financial report of "Sopharma" AD for 2023 in ESF format	13,05	0,00
2024-04-22	SPH Sales revenues of Sopharma AD for March 2024	13,70	0,00
2024-04-01	SPH Presentation of the Annual Audited Individual Financial Statements of “Sopharma” AD as at 31 December 2022	13,40	0,00
2024-03-20	SPH Sales revenues for February 2024	14,40	-3,13
2024-03-12	SPH Incoming transfer from capital increase subject to exercise of warrants from issue BG9200001212	14,00	-1,43
2024-03-11	SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 08 March 2024 on the acquisition of shares from a capital increase	13,80	+1,45
2024-02-29	SPH Consolidated financial report as of 31 December 2023	13,70	-2,19
2024-02-27	SPH Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212	13,40	+2,99
2024-02-22	SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the acquisition of shares from a temporary issue/exercise of warrants	13,75	-0,73
2024-02-22	SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the exercise of warrants in a capital increase under the condition	13,75	-0,73

Wszystke komunikaty